To evaluate the efficacy and safety of KW-3357 with concomitant use of heparin using multi-center, non-comparative, open-label method in patients diagnosed as disseminated intravascular coagulation (DIC) by Japanese Association for Acute Medicine-defined DIC criteria.
Age range
20 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Safety
Timeframe: up to 6 days (or discontinuation)
DIC resolution
Timeframe: 6 days (or discontinuation)
DIC score
Timeframe: Screening, 2, 3, 4, 5, 6 days (or discontinuation)
Mortality
Timeframe: 28 days
Organ symptoms
Timeframe: Screening, 4, 6 days (or discontinuation)
Severity
Timeframe: Screening, 4, 6 days (or discontinuation)
Plasma antithrombin activity
Timeframe: Screening, 2, 3, 4, 5, 6 days (or discontinuation)